TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35758944

Group type: EXPERIMENTAL
Intervention: Choline alfoscerate (Cereton)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34593120

Group type: EXPERIMENTAL
Intervention: Initial triple therapy (macitentan, tadalafil, and selexipag)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Initial double therapy (macitentan, tadalafil, and placebo)
Number of subjects: 247
Study: 35569079

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy with intracorporeal reconstruction
Number of subjects: 338

Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy
Number of subjects: 338
Study: 34273682

Group type: EXPERIMENTAL
Intervention: Juçara fruit juice (JFJ) 250 mL
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15
Study: 33559485

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 21162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study: 32041605

Group type: EXPERIMENTAL
Intervention: Biological with best practice prevention (B+P)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Prevention Alone (PA)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Conventional with best practice prevention (C+P)
Number of subjects: 1058
Study: 34139916

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32248829

Group type: EXPERIMENTAL
Intervention: Tocilizumab (subcutaneously at 162 mg/week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prednisone (orally at 10 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tocilizumab and Prednisone
Number of subjects: 120
Study: 34961729

Group type: EXPERIMENTAL
Intervention: app + telehealth
Number of subjects: 37

Group type: COMPARATOR
Intervention: app
Number of subjects: 37
Study: 34237274

Group type: EXPERIMENTAL
Intervention: Point mutations abrogating spectrin-repeat-mediated dimerization of Kar9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphomimetic substitution of six Cdk1 sites surrounding the Kar9 dimerization interface
Number of subjects: 0
Study: 32569643

Group type: EXPERIMENTAL
Intervention: SafeCare
Number of subjects: 288

Group type: COMPARATOR
Intervention: SAU
Number of subjects: 288
Study: 32234011

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment and accelerometer use for measuring physical activity (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline assessments followed by three annual follow-up assessments
Number of subjects: 0
Study: 35193718

Group type: EXPERIMENTAL
Intervention: Brazil and cashew nuts group (BN-Group): Energy-restricted diet containing daily 45 g of nuts (15 g of Brazil nuts + 30 g of cashew nuts), n=21
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brazil and cashew nuts group (BN-Group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group: Energy-restricted diet without nuts, n=19
Number of subjects: 40
Study: 34412536

Group type: EXPERIMENTAL
Intervention: Motor-control group (scapular-focused exercise + conscious control of scapular orientation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Regular-exercise group (scapular-focused exercises only)
Number of subjects: 36
Study: 33052965

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (MAP) consisting of 2.5 trauma-focused psychotherapy sessions and two 8-hour sessions with MDMA (mean dose of 125 mg) followed by 3.5 integration sessions
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (MAP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Inactive placebo or 25–40 mg of MDMA
Number of subjects: 105
Study: 34281074

Group type: EXPERIMENTAL
Intervention: 100% Physical Guidance (PG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 75% Physical Guidance (PG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 50% Physical Guidance (PG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 25% Physical Guidance (PG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0% Physical Guidance (PG)
Number of subjects: 25
Study: 35166212

Group type: EXPERIMENTAL
Intervention: Trigger point therapy (TriT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acupoint therapy (AcuT)
Number of subjects: 100
Study: 33378499

Group type: EXPERIMENTAL
Intervention: Connecticut intrusion arch (CIA) without a cinch back
Number of subjects: 44

Group type: COMPARATOR
Intervention: Connecticut intrusion arch (CIA) with a cinch back
Number of subjects: 44
Study: 34933532

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) consumption
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no NAC consumption)
Number of subjects: 200
Study: 34677153

Group type: EXPERIMENTAL
Intervention: Ozone group (received lung disinfection technique with ozone and standard COVID-19 treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not treated with ozone, only received standard COVID-19 treatment)
Number of subjects: 30
Study: 34962461

Group type: EXPERIMENTAL
Intervention: A connection mode (pre‐membrane‐pre‐pump connection)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: B connection mode (post‐membrane‐post‐pump connection)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both connection modes
Number of subjects: 21
Study: 36608971

Group type: EXPERIMENTAL
Intervention: 1-week online intervention with three functionality-focused writing exercises
Number of subjects: 103

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 103
Study: 32949144

Group type: EXPERIMENTAL
Intervention: Irrigation with saline (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Irrigation with saline followed by corticosteroid application (triamcinolone acetonide in saline) (saline/TA, n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no irrigation, n = 15)
Number of subjects: 45
Study: 32464266

Group type: EXPERIMENTAL
Intervention: Conventional photodynamic therapy (C‐PDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Daylight photodynamic therapy (DL‐PDT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 34838460

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Number of subjects: 0
Study: 33864735

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 μg per actuation, total dose of 1600 μg, two puffs twice per day)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study: 33710277

Group type: EXPERIMENTAL
Intervention: 120 mg CBD and 5.4 mg THC daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 240 mg CBD and 10.8 mg THC daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 360 mg CBD and 16.2 mg THC daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 480 mg CBD and 21.6 mg THC daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 34329455

Group type: EXPERIMENTAL
Intervention: Alfentanil + Pregabalin (300 mg orally)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 31
Study: 35767811

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithms for predicting conversion to arthroplasty
Number of subjects: 875

Group type: COMPARATOR
Intervention: Sliding hip screw or cancellous screws for internal fixation (control)
Number of subjects: 875
Study: 33383228

Group type: EXPERIMENTAL
Intervention: Rhythm control strategies
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Rate control strategies
Number of subjects: 4060
Study: 35760666

Group type: EXPERIMENTAL
Intervention: Auto-cross-linked hyaluronic acid gel
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (oestradiol and intrauterine balloon insertion)
Number of subjects: 171
Study: 34146646

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Nutritional warnings
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Health-related cues (nutrient claims and images of seeds and wheat)
Number of subjects: 510
Study: 35149565

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 180
Study: 33612282

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study: 35246416

Group type: EXPERIMENTAL
Intervention: Home-based intervention led by trained health extension workers every 2 months for 9 months
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Home-based intervention led by trained health extension workers
Number of subjects: 456
Study: 32045316

Group type: EXPERIMENTAL
Intervention: Nanocarbon group (n=51)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 93
Study: 36226670

Group type: EXPERIMENTAL
Intervention: Hand grip training program (HG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care (CG)
Number of subjects: 0
Study: 33990144

Group type: EXPERIMENTAL
Intervention: Fremanezumab (quarterly)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Fremanezumab (monthly)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 832
Study: 32314464

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (20 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Glimepiride (0.5 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 64
Study: 36445874

Group type: EXPERIMENTAL
Intervention: High flavonoid pre-workout beverage (490 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low flavonoid pre-workout beverage (5 mg)
Number of subjects: 12
Study: 33945820

Group type: EXPERIMENTAL
Intervention: Reproxalap 0.25%
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Reproxalap 0.5%
Number of subjects: 318

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 318
Study: 35594564

Group type: EXPERIMENTAL
Intervention: COVID-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Influenza
Number of subjects: 0
Study: 33735740

Group type: EXPERIMENTAL
Intervention: 10 Hz active rTMS stimulation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham rTMS stimulation
Number of subjects: 38
Study: 32979294

Group type: EXPERIMENTAL
Intervention: Mindfulness app (10–20 min/day) or webinar‐based mindfulness course for 6 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Waitlist control group (usual care)
Number of subjects: 142
Study: 34980546

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg), Vitamin D3 (400 IU), Collagen Peptides (5 g)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Calcium (500 mg), Vitamin D3 (400 IU)
Number of subjects: 51
Study: 32394651

Group type: EXPERIMENTAL
Intervention: Acupuncture at Shenmen (HT 7) and Baihui (GV 20) in group A
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Acupuncture at Sanyinjiao (SP 6) and Baihui (GV 20) in group B
Number of subjects: 333

Group type: COMPARATOR
Intervention: Acupuncture at non‐acupoint and Baihui (GV 20) in group C
Number of subjects: 333
Study: 34687122

Group type: EXPERIMENTAL
Intervention: 8-week supervised therapeutic exercise program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 36190598

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA (Group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Turbo flash scan using iohexol (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA (Group C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA (Group C40keV)
Number of subjects: 66
Study: 33990969

Group type: COMPARATOR
Intervention: TAK-418 (5-60 mg single rising dose)
Number of subjects: 54

Group type: COMPARATOR
Intervention: TAK-418 (120-160 mg single rising dose)
Number of subjects: 54

Group type: COMPARATOR
Intervention: TAK-418 (20-160 mg once daily for 10 days)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: TAK-418
Number of subjects: 54
Study: 32698830

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intratympanic glucocorticoids
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-reported vestibular dysfunction symptoms
Number of subjects: 72
Study: 35231887

Group type: EXPERIMENTAL
Intervention: Dapsone (100 mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (aluminum hydroxide suspension, 2.5 ml daily)
Number of subjects: 48
Study: 33400092

Group type: EXPERIMENTAL
Intervention: HAdV‐7 strains from children with ARI
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: HAdV‐7 strains
Number of subjects: 57
Study: 34340694

Group type: EXPERIMENTAL
Intervention: Financial incentives for up to 3 months postpartum offering up to £120 of incentives (£60 for the participant and £60 for a significant other support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial incentives for up to 12 months postpartum with up to £300 of incentives (£240 for the participant and £60 for a significant other support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No incentives/usual care
Number of subjects: 0
Study: 32344891

Group type: EXPERIMENTAL
Intervention: Bone Graft Surgery (BGS)
Number of subjects: 60
Study: 34798073

Group type: EXPERIMENTAL
Intervention: Nudges
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control
Number of subjects: 182
Study: 34676982

Group type: EXPERIMENTAL
Intervention: Ginkgolide
Number of subjects: 936

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study: 35451544

Group type: EXPERIMENTAL
Intervention: Planning as a self-regulation strategy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not planning
Number of subjects: 19
Study: 36141910

Group type: EXPERIMENTAL
Intervention: Family-centred intervention 'Are you too sweet?'
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Post-intervention semi-structured interviews
Number of subjects: 24
Study: 33704919

Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg every 6 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridoxic acid (PDA) and homovanillic acid (HVA) as biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDA model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-based simulations and power calculations
Number of subjects: 0
Study: 36041982

Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training with a mechanical threshold device in addition to usual care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 70
Study: 32978652

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing via suprapatellar approach (IMN group)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Locked compressive plate (LCP group)
Number of subjects: 328
Study: 32589828

Group type: EXPERIMENTAL
Intervention: SAMe (200 mg) plus Lactobacillus plantarum HEAL9 (1 × 10⁹ CFU)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 35749277

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 565
Study: 33735206

Group type: EXPERIMENTAL
Intervention: AGL-FTIC
Number of subjects: 693

Group type: COMPARATOR
Intervention: early-FTIC
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Not achieving composite outcome
Number of subjects: 693
Study: 32382928

Group type: EXPERIMENTAL
Intervention: GuttaFlow Bioseal
Number of subjects: 48

Group type: COMPARATOR
Intervention: BioRoot RCS
Number of subjects: 48
Study: 36270095

Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg once daily for five days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 33135866

Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented arm (two 4 oz. servings of the probiotic yogurt product daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Probiotic-restricted arm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented arm
Number of subjects: 20
Study: 33064621

Group type: EXPERIMENTAL
Intervention: Music-based approach to teach pursed-lip breathing; patients meet twice weekly for eight weeks for melodica instruction, group music-making, and COPD education.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education-control group; details not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group; details not specified.
Number of subjects: 0
Study: 32892271

Group type: EXPERIMENTAL
Intervention: Peer Feedback (PFG)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Expert Feedback (EFG)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Video-Guided Learning (VLG)
Number of subjects: 130
Study: 32329651

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 22
Study: 33327246

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 82

Group type: COMPARATOR
Intervention: Propofol (Control)
Number of subjects: 82
Study: 33965574

Group type: EXPERIMENTAL
Intervention: Naldemedine
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1095
Study: 33542047

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 75
Study: 34187296

Group type: EXPERIMENTAL
Intervention: Optimal NRS (based on greatest reduction in WOB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive pressure (nCPAP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxygen (O2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard noninvasive parameters)
Number of subjects: 30
Study: 32525048

Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: 0.025% atropine
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 33453076

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 615916050

Group type: EXPERIMENTAL
Intervention: ETDRS PRP plus IVR (SS-PRP group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PASCAL PRP plus IVR (MS-PRP group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Only IVR (IVR group)
Number of subjects: 40
Study: 36047511

Group type: EXPERIMENTAL
Intervention: Sodium alginate 0.03 g per kg body weight per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sodium alginate 0.06 g per kg body weight per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metformin 500 mg day‐1 for 60 days (positive control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sodium alginate (both dosages)
Number of subjects: 30
Study: 33576172

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 809601

Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 809601
Study: 34042773

Group type: EXPERIMENTAL
Intervention: HL7 FHIR standard implementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32078063

Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration (UIC) < 100 μg/L
Number of subjects: 75653

Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration (UIC) 100-199 μg/L
Number of subjects: 75653

Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration (UIC) 200-299 μg/L
Number of subjects: 75653

Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration (UIC) ≥ 300 μg/L
Number of subjects: 75653

Group type: EXPERIMENTAL
Intervention: More than adequate iodine group
Number of subjects: 75653

Group type: EXPERIMENTAL
Intervention: Excessive iodine group
Number of subjects: 75653

Group type: COMPARATOR
Intervention: Adequate iodine (AI) group
Number of subjects: 75653
Study: 33374017

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PLEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No plasma exchange (control group)
Number of subjects: 0
Study: 34897950

Group type: EXPERIMENTAL
Intervention: Widespread pain
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Number of painful sites
Number of subjects: 299
Study: 35324220

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention before viewing psychoeducation
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Single session of group counseling
Number of subjects: 172

Group type: COMPARATOR
Intervention: Psychoeducation only (without self-affirmation)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Wait-list control condition (no intervention)
Number of subjects: 172
Study: 33167953

Group type: EXPERIMENTAL
Intervention: Popular real fit influencer
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fictitious fit influencer
Number of subjects: 154
Study: 34985846

Group type: EXPERIMENTAL
Intervention: Anodal tDCS + active iTBS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anodal tDCS + sham iTBS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sham tDCS + active iTBS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS + sham iTBS
Number of subjects: 30
Study: 32937260

Group type: EXPERIMENTAL
Intervention: Verbal Imaginal Exposure (IE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 20
Study: 34525408

Group type: EXPERIMENTAL
Intervention: Registry use in RCTs
Number of subjects: 47